Intestinal dysbiosis and probiotic applications in autoimmune diseases.

Autor: de Oliveira GLV; Microbiome Study Group, School of Health Sciences Dr Paulo Prata, Barretos, São Paulo, Brazil., Leite AZ; Microbiome Study Group, School of Health Sciences Dr Paulo Prata, Barretos, São Paulo, Brazil., Higuchi BS; Microbiome Study Group, School of Health Sciences Dr Paulo Prata, Barretos, São Paulo, Brazil., Gonzaga MI; Microbiome Study Group, School of Health Sciences Dr Paulo Prata, Barretos, São Paulo, Brazil.; Barretos Cancer Hospital, Barretos, São Paulo, Brazil., Mariano VS; Barretos Cancer Hospital, Barretos, São Paulo, Brazil.
Jazyk: angličtina
Zdroj: Immunology [Immunology] 2017 Sep; Vol. 152 (1), pp. 1-12. Date of Electronic Publication: 2017 Jun 29.
DOI: 10.1111/imm.12765
Abstrakt: In humans, a complex interaction between the host immune system and commensal microbiota is required to maintain gut homeostasis. In this symbiotic relationship, the microbiota provides carbohydrate fermentation and digestion, vitamin synthesis and gut-associated lymphoid tissue development, as well as preventing colonization by pathobionts, whereas the host offers a niche and nutrients for the survival of the microbiota. However, when this mutualistic relationship is compromised and an altered interaction between immune cells and microorganisms occurs, the gut microbiota may cause or contribute to the establishment of infectious diseases and trigger autoimmune diseases. Researchers have made efforts to clarify the role of the microbiota in autoimmune disease development and find new therapeutic approaches to treat immune-mediated diseases. However, the exact mechanisms involved in the dysbiosis and breakdown of the gut epithelial barrier are currently unknown. Here, we provide a general overview of studies describing gut microbiota perturbations in animal models of autoimmune diseases, such as type 1 diabetes, multiple sclerosis, rheumatoid arthritis and systemic lupus erythematosus. Moreover, we include the main studies concerning dysbiosis in humans and a critical discussion of the existing data on the use of probiotics in these autoimmune diseases.
(© 2017 John Wiley & Sons Ltd.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje